Antithrombotic therapy after transcatheter aortic valve implantation

References

• Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. EuroIntervention. 2022;17(14):e1126–e1196.
   PubMed Web of Science ®Google Scholar
• Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease. J Am Coll Cardiol. 2021;77(4):e25–e197.
   PubMed Web of Science ®Google Scholar
• Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597–1607.
   PubMed Web of Science ®Google Scholar
• Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370(19):1790–1798.
   PubMed Web of Science ®Google Scholar
• Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364(23):2187–2198.
   PubMed Web of Science ®Google Scholar
• Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374(17):1609–1620.
   PubMed Web of Science ®Google Scholar
• Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017;376(14): 1321–1331.
   PubMed Web of Science ®Google Scholar
• Fairbairn T, Kemp I, Young A, et al. Effect of transcatheter aortic valve implantation vs surgical aortic valve replacement on all-cause mortality in patients with aortic stenosis. JAMA. 2022;327(19):1875–1887.
   PubMed Web of Science ®Google Scholar
• Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695–1705.
   PubMed Web of Science ®Google Scholar
• Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380(18):1706–1715.
   PubMed Web of Science ®Google Scholar
• Thyregod HGH, Steinbrüchel DA, Ihlemann N et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis. J Am Coll Cardiol. 2015;65(20):2184–2194.
   PubMed Web of Science ®Google Scholar
• Durko AP, Osnabrugge RL, Van Mieghem NM, et al. Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections. Eur Heart J. 2018;39(28):2635–2642.
   PubMed Web of Science ®Google Scholar
• Eltchaninoff H, Gilard M, Cribier A. TAVI at 20: how a crazy idea led to a clinical revolution. EuroIntervention. 2022;18(1):15–18.
   PubMed Web of Science ®Google Scholar
• Mangieri A, Montalto C, Poletti E, et al. Thrombotic versus bleeding risk after transcatheter aortic valve replacement. J Am Coll Cardiol. 2019;74(16):2088–2101.
   PubMed Web of Science ®Google Scholar
• Greco A, Capranzano P, Barbanti M, et al. Antithrombotic pharmacotherapy after transcatheter aortic valve implantation: an update. Expert Rev Cardiovasc Ther. 2019;17(7):479–496.
   PubMed Web of Science ®Google Scholar
• Généreux P, Piazza N, Alu MC, et al. Valve academic research consortium 3: updated endpoint definitions for aortic valve clinical research. Eur Heart J. 2021;42(19):1825–1857.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Collet J-P, Dangas G, et al. Antithrombotic therapy after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2021;14(15):1688–1703.
   PubMed Web of Science ®Google Scholar
• Fanaroff AC, Manandhar P, Holmes DR, et al. Peripheral artery disease and transcatheter aortic valve replacement outcomes. Circ Cardiovasc Interv. 2017;10(10):e005456.
   PubMed Web of Science ®Google Scholar
• Steinvil A, Leshem-Rubinow E, Abramowitz Y, et al. Prevalence and predictors of carotid artery stenosis in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2014;84:1007–1012.
   PubMed Web of Science ®Google Scholar
• Biviano AB, Nazif T, Dizon J, et al. Atrial fibrillation is associated with increased mortality in patients undergoing transcatheter aortic valve replacement. Circ Cardiovasc Interv. 2016;9(1):e002766.
   PubMed Web of Science ®Google Scholar
• Tarantini G, Mojoli M, Urena M, et al. Atrial fibrillation in patients undergoing transcatheter aortic valve implantation: epidemiology, timing, predictors, and outcome. Eur Heart J 2016 ehw456.
   Google Scholar
• Jørgensen TH, Thyregod HGH, Tarp JB, et al. Temporal changes of new-onset atrial fibrillation in patients randomized to surgical or transcatheter aortic valve replacement. Int J Cardiol. 2017;234:16–21.
   PubMed Web of Science ®Google Scholar
• Rodés-Cabau J, Gutiérrez M, Bagur R, et al. Incidence, predictive factors, and prognostic value of myocardial injury following uncomplicated transcatheter aortic valve implantation. J Am Coll Cardiol. 2011;57(20):1988–1999.
   PubMed Web of Science ®Google Scholar
• Michail M, Cameron JN, Nerlekar N, et al. Periprocedural myocardial injury predicts short- and long-term mortality in patients undergoing transcatheter aortic valve replacement. Circ Cardiovasc Interv. 2018;11(11):e007106.
   PubMed Web of Science ®Google Scholar
• Faroux L, Munoz-Garcia E, Serra V, et al. Acute coronary syndrome following transcatheter aortic valve replacement. Circ Cardiovasc Interv. 2020;13(2):e008620.
   PubMed Web of Science ®Google Scholar
• Pighi M, Lunardi M, Pesarini G, et al. Intravascular ultrasound assessment of coronary ostia following valve-in-valve transcatheter aortic valve implantation. EuroIntervention. 2021;16(14):1148–1151.
   PubMed Web of Science ®Google Scholar
• Buzzatti N, Montorfano M, Romano V, et al. A computed tomography study of coronary access and coronary obstruction after redo transcatheter aortic valve implantation. EuroIntervention. 2020;16(12):e1005–e1013.
   PubMed Web of Science ®Google Scholar
• Kitamura M, Majunke N, Holzhey D, et al. Systematic use of intentional leaflet laceration to prevent TAVI-induced coronary obstruction: feasibility and early clinical outcomes of the BASILICA technique. EuroIntervention. 2020;16(8):682–690.
   PubMed Web of Science ®Google Scholar
• Rodés-Cabau J, Ribeiro HB. Consolidating the BASILICA technique in TAVI patients at risk of coronary obstruction. EuroIntervention. 2020;16(8):617–619.
   PubMed Web of Science ®Google Scholar
• Tang GHL, Zaid S. Coronary re-access after redo TAVI: a proposed classification to simplify evaluation. EuroIntervention. 2020;16(12):e960–e962.
   PubMed Web of Science ®Google Scholar
• Kumar A, Sammour Y, Reginauld S, et al. Adverse clinical outcomes in patients undergoing both PCI and TAVR: analysis from a pooled multi-center registry. Catheter Cardiovasc Interv. 2021;97(3):529–539.
   PubMed Web of Science ®Google Scholar
• Patterson T, Clayton T, Dodd M, et al. ACTIVATION (percutaneous coronary inTervention prIor to transcatheter aortic VAlve implantaTION). JACC Cardiovasc Interv. 2021;14(18):1965–1974.
   PubMed Web of Science ®Google Scholar
• Hindricks G, Potpara T, Dagres N, et al. ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS). Eur Heart J. 2020;2021(42):373–498.
   Google Scholar
• Linder M, Voigtländer L, Schneeberger Y, et al. Spontaneous echo contrast, left atrial appendage thrombus and stroke in patients undergoing transcatheter aortic valve implantation. EuroIntervention. 2021;16(13):1114–1122.
   PubMed Web of Science ®Google Scholar
• Fröhlich GM, Endres M, Falk V, et al. Evaluation of cerebral thromboembolism after transcatheter aortic valve replacement (EARTH TAVR): a serial magnetic resonance imaging evaluation as substudy of the GALILEO trial. Circ Cardiovasc Interv. 2021;14(9):e011074.
   PubMed Web of Science ®Google Scholar
• Auffret V, Regueiro A, Del Trigo M, et al. Predictors of early cerebrovascular events in patients with aortic stenosis undergoing transcatheter aortic valve replacement. J Am Coll Cardiol. 2016;68(7):673–684.
   PubMed Web of Science ®Google Scholar
• Stortecky S, and Windecker S. Stroke: An Infrequent but Devastating Complication in Cardiovascular Interventions. Circulation. 2012;126(25):2921–2924.
   PubMed Web of Science ®Google Scholar
• Woldendorp K, Indja B, Bannon PG, et al. Silent brain infarcts and early cognitive outcomes after transcatheter aortic valve implantation: a systematic review and meta-analysis. Eur Heart J. 2021;42(10):1004–1015.
   PubMed Web of Science ®Google Scholar
• Kroon H, von der Thusen JH, Ziviello F, et al. Heterogeneity of debris captured by cerebral embolic protection filters during TAVI. EuroIntervention. 2021;16(14):1141–1147.
   PubMed Web of Science ®Google Scholar
• Vavuranakis MA, Kalantzis C, Voudris V, et al. Comparison of ticagrelor versus clopidogrel on cerebrovascular microembolic events and platelet inhibition during transcatheter aortic valve implantation. Am J Cardiol. 2021;154:78–85.
   PubMed Web of Science ®Google Scholar
• Bagur R, Solo K, Alghofaili S, et al. Cerebral embolic protection devices during transcatheter aortic valve implantation. Stroke. 2017;48(5):1306–1315.
   PubMed Web of Science ®Google Scholar
• Ahmad Y, Howard JP. Meta-analysis of usefulness of cerebral embolic protection during transcatheter aortic valve implantation. Am J Cardiol. 2021;146:69–73.
   PubMed Web of Science ®Google Scholar
• Butala NM, Makkar R, Secemsky EA, et al. cerebral embolic protection and outcomes of transcatheter aortic valve replacement: results from the transcatheter Valve therapy registry. Circulation. 2021;143(23):2229–2240.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Petronio AS, Prendergast B, et al. Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European association of percutaneous cardiovascular interventions. Eur J Cardio Thoracic Surg. 2017;52:408–417.
   PubMed Web of Science ®Google Scholar
• Jilaihawi H, Asch FM, Manasse E, et al. Systematic CT methodology for the evaluation of subclinical leaflet thrombosis. JACC Cardiovasc Imaging. 2017;10(4):461–470.
   PubMed Web of Science ®Google Scholar
• Fukui M, Bapat V, Garcia S, et al. Deformation of transcatheter aortic valve prostheses: implications for hypoattenuating leaflet thickening and clinical outcomes. Circulation. 2022. ePub [ahead of print].
   Web of Science ®Google Scholar
• Makkar RR, Blanke P, Leipsic J, et al. Subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic valves. J Am Coll Cardiol. 2020;75(24):3003–3015.
   PubMed Web of Science ®Google Scholar
• Garcia S, Fukui M, Dworak MW, et al. Clinical impact of hypoattenuating leaflet thickening after transcatheter aortic valve replacement. Circ Cardiovasc Interv. 2022 ePub [ahead of print]; 15(3).
   Web of Science ®Google Scholar
• Hein M, Schoechlin S, Schulz U, et al. Long-term follow-up of hypoattenuated leaflet thickening after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2022;15(11):1113–1122.
   PubMed Web of Science ®Google Scholar
• Bogyi M, Schernthaner RE, Loewe C, et al. Subclinical leaflet thrombosis after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2021;14(24):2643–2656.
   PubMed Web of Science ®Google Scholar
• De Backer O, Dangas GD, Jilaihawi H, et al. Reduced leaflet motion after transcatheter aortic-valve replacement. N Engl J Med. 2020;382(2):130–139.
   PubMed Web of Science ®Google Scholar
• Greco A, The CD. ATLANTIS randomized trial: apixaban versus standard of care after TAVI. Card Interv Today. 2021;15:51–56.
   Google Scholar
• Park D-W, Ahn J-M, Kang D-Y, et al. Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR: the ADAPT-TAVR randomized clinical trial. Circulation. 2022. ePub [ahead of print].
   Web of Science ®Google Scholar
• Puri R, Auffret V, Rodés-Cabau J. Bioprosthetic Valve Thrombosis. J Am Coll Cardiol. 2017;69(17):2193–2211.
   PubMed Web of Science ®Google Scholar
• Franzone A, Pilgrim T, Haynes AG, et al. Transcatheter aortic valve thrombosis: incidence, clinical presentation and long-term outcomes. Eur Hear J - Cardiovasc Imaging. 2018;19(4):398–404.
   PubMed Web of Science ®Google Scholar
• Jose J, Sulimov DS, El-Mawardy M, et al. Clinical bioprosthetic heart valve thrombosis after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2017;10(7):686–697.
   PubMed Web of Science ®Google Scholar
• Hafiz AM, Kalra A, Ramadan R, et al. Clinical or symptomatic leaflet thrombosis following transcatheter aortic valve replacement: insights from the U.S. FDA MAUDE database. Struct Hear. 2017;1(5–6):256–264.
   Google Scholar
• Pilgrim T, Stortecky S, Luterbacher F, et al. Transcatheter aortic valve implantation and bleeding: incidence, predictors and prognosis. J Thromb Thrombolysis. 2013;35(4):456–462.
   PubMed Web of Science ®Google Scholar
• Généreux P, Cohen DJ, Mack M, et al. Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement. J Am Coll Cardiol. 2014;64(24):2605–2615.
   PubMed Web of Science ®Google Scholar
• Genereux P, Giustino G, Witzenbichler B, et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. J Am Coll Cardiol. 2015;66(9):1036–1045.
   PubMed Web of Science ®Google Scholar
• Piccolo R, Pilgrim T, Franzone A, et al. Frequency, timing, and impact of access-site and non–access-site bleeding on mortality among patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2017;10(14):1436–1446.
   PubMed Web of Science ®Google Scholar
• Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123(23):2736–2747.
   PubMed Web of Science ®Google Scholar
• Greco A, Capodanno D. Anticoagulation after transcatheter aortic valve implantation: current status. Interv Cardiol Rev. 2020;15:e02.
   PubMedGoogle Scholar
• Konigstein M, Ben-Assa E, Banai S, et al. Periprocedural bleeding, acute kidney injury, and long-term mortality after transcatheter aortic valve implantation. Can J Cardiol. 2015;31(1):56–62.
   PubMed Web of Science ®Google Scholar
• Borz B, Durand E, Godin M, et al. Incidence, predictors and impact of bleeding after transcatheter aortic valve implantation using the balloon-expandable edwards prosthesis. Heart. 2013;99(12):860–865.
   PubMed Web of Science ®Google Scholar
• Honda Y, Yamawaki M, Nakano T, et al. Successfully managed access-site complication was not associated with worse outcome after percutaneous transfemoral transcatheter aortic valve implantation: up-to-date insights from the ocean-tavi registry. Cardiovasc Revascularization Med. 2022;38:11–18.
   PubMed Web of Science ®Google Scholar
• Van Mieghem NM, Tchetche D, Chieffo A, et al. Incidence, predictors, and implications of access site complications with transfemoral transcatheter aortic valve implantation. Am J Cardiol. 2012;110(9):1361–1367.
   PubMed Web of Science ®Google Scholar
• De Larochellière H, Puri R, Eikelboom JW, et al. Blood disorders in patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2019;12(1):1–11.
   PubMed Web of Science ®Google Scholar
• Van Belle E, Rauch A, Vincent F, et al. Von Willebrand factor multimers during transcatheter aortic-valve replacement. N Engl J Med. 2016;375(4):335–344.
   PubMed Web of Science ®Google Scholar
• Goltstein L, Rooijakkers M, Gortjes N, et al. Reduction of gastrointestinal bleeding in patients with Heyde syndrome undergoing transcatheter aortic valve implantation. Circ Cardiovasc Interv. 2022 ePub [ahead of print]; 157
   PubMed Web of Science ®Google Scholar
• Mehran R, Sorrentino S, and Claessen BE, et al. Paravalvular Leak: An Interesting Interplay of Acquired vWF-Disease and Late Bleeding After TAVR. J Am Coll Cardiol. 2018;72(18):2149–2151.
   PubMed Web of Science ®Google Scholar
• Van Belle E, Debry N, Vincent F, et al. Cerebral microbleeds during transcatheter aortic valve replacement: a prospective magnetic resonance imaging cohort. Circulation. 2022; ePub [ahead of print].
   PubMed Web of Science ®Google Scholar
• Greco A, and Capodanno D. Cerebrovascular disease - what is the role of DAPT for prevention and treatment of ischemic stroke? Dual antiplatelet therapy for coronary and peripheral artery disease. First edition. Amsterdam: Elsevier; 2021. p. 91–110.
   Google Scholar
• Ussia GP, Scarabelli M, Mulè M, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol. 2011;108(12):1772–1776.
   PubMed Web of Science ®Google Scholar
• Stabile E, Pucciarelli A, Cota L, et al. SAT-TAVI (single antiplatelet therapy for TAVI) study: a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. Int J Cardiol. 2014;174(3):624–627.
   PubMed Web of Science ®Google Scholar
• Rodés-Cabau J, Masson J-B, Welsh RC, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve. JACC Cardiovasc Interv. 2017;10(13):1357–1365.
   PubMed Web of Science ®Google Scholar
• Brouwer J, Nijenhuis VJ, Delewi R, et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med. 2020;383(15):1447–1457.
   PubMed Web of Science ®Google Scholar
• Jimenez Diaz VA, Tello-Montoliu A, Moreno R, et al. Assessment of platelet reactivity after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2019;12(1):22–32.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Greco A. Platelet function testing after transcatheter aortic valve implantation. Thromb Haemost. 2018;118(10):1681–1685.
   PubMed Web of Science ®Google Scholar
• Overtchouk P, Guedeney P, Rouanet S, et al. Long-term mortality and early valve dysfunction according to anticoagulation use. J Am Coll Cardiol. 2019;73(1):13–21.
   PubMed Web of Science ®Google Scholar
• Jimenez Diaz VA on behalf of the AI. Short-course dual antiplatelet therapy versus oral anticoagulation to prevent cerebral embolism after transcatheter aortic valve replacement. Present. TCT 2019. 2019 Sept 28. San Fr. CA.
   Google Scholar
• Rogers T, Shults C, Torguson R, et al. Randomized trial of aspirin versus warfarin after transcatheter aortic valve replacement in low-risk patients. Circ Cardiovasc Interv. 2021;14(1):e009983.
   PubMed Web of Science ®Google Scholar
• Dangas GD, Tijssen JGP, Wöhrle J, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med. 2020;382(2):120–129.
   PubMed Web of Science ®Google Scholar
• Collet J-P, Van Belle E, Thiele H, et al. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur Heart J. 2022;ehac242.
   Google Scholar
• Chakravarty T, Søndergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017;389(10087):2383–2392.
   PubMed Web of Science ®Google Scholar
• Kosmidou I, Liu Y, Alu MC, et al. Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve replacement in patients with atrial FIBrillation. JACC Cardiovasc Interv. 2019;12(16):1580–1589.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Greco A. Stroke after transcatheter aortic valve replacement: a multifactorial phenomenon. JACC Cardiovasc Interv. 2019;12(16):1590–1593.
   PubMed Web of Science ®Google Scholar
• Nijenhuis VJ, Brouwer J, Delewi R, et al., Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med. 2020;382(18):1696–1707.
   PubMed Web of Science ®Google Scholar
• Van Mieghem NM, Unverdorben M, Hengstenberg C, et al., Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med. 2021;385(23):2150–2160.
   PubMed Web of Science ®Google Scholar
• Van Mieghem NM, Reardon MJ, Yakubov SJ, et al. Clinical outcomes of TAVI or SAVR in men and women with aortic stenosis at intermediate operative risk: a post hoc analysis of the randomised SURTAVI trial. EuroIntervention. 2020;16(10):833–841.
   PubMed Web of Science ®Google Scholar
• Greco A, Capodanno D. Differences in coronary artery disease and outcomes of percutaneous coronary intervention with drug-eluting stents in women and men. Expert Rev Cardiovasc Ther. 2021;19(4):301–312.
   PubMed Web of Science ®Google Scholar
• Capodanno D, and Greco A. Risk stratification for bleeding in the elderly with acute coronary syndrome: not so simple. Thromb Haemost. 2018;118(6):949–952.
   Web of Science ®Google Scholar
• Greco A, Capodanno D, Angiolillo D. The conundrum surrounding racial differences on ischaemic and bleeding risk with dual anti-platelet therapy. Thromb Haemost. 2019;119(1):009–013.
   PubMed Web of Science ®Google Scholar
• Collet J-P, Thiele H, Barbato E, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020;2021(42):1289–1367.
   Google Scholar
• Knuuti J, Wijns W, Saraste A, et al. ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2019;2020(41):407–477.
   Google Scholar
• ten Berg J, Sibbing D, Rocca B, et al. Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collabor. Eur Heart J. 2021;42(23):2265–2269.
   PubMed Web of Science ®Google Scholar
• Laudani C, Greco A, Occhipinti G, et al. Short duration of DAPT versus de-escalation after percutaneous coronary intervention for acute coronary syndromes. JACC Cardiovasc Interv. 2022;15(3):268–277.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Di Maio M, Greco A, et al. Safety and efficacy of double antithrombotic therapy with non–vitamin K antagonist oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and meta‐analysis. J Am Heart Assoc. 2020;9(16):e017212.
   PubMed Web of Science ®Google Scholar
• Garot P, Neylon A, Morice M-C, et al. Bleeding risk differences after TAVR according to the ARC-HBR criteria: insights from SCOPE 2. EuroIntervention. 2022. ePub [ahead of print].
   Web of Science ®Google Scholar
• Attinger-Toller A, Maisano F, Senn O, et al. One-Stop shop. JACC Cardiovasc Interv. 2016;9(14):1487–1495.
   PubMedGoogle Scholar